Oxford University Hospitals saves nearly £5m by moving to biosimilar medicine for gastroenterology patients

Gastroenterology colleagues at Oxford University Hospitals NHS Foundation Trust (OUH) have successfully introduced another biosimilar medicine (Ustekinumab) for the treatment of patients with Inflammatory Bowel Disease (IBD), as part of ongoing efforts to enhance care and improve value for the NHS.

This is the third biosimilar product to be implemented at OUH for IBD, which includes long-term conditions such as Crohn’s disease and ulcerative colitis. The move is part of a nationally-supported approach to safely and effectively expand the use of biosimilar medicines across the NHS.
Biosimilars are highly similar versions of already approved biological medicines. They are assessed and authorised according to the same rigorous standards of pharmaceutical quality, safety, and clinical effectiveness that apply to all biological treatments.

Dr Oliver Brain, Consultant Gastroenterologist at OUH, said: “Good disease control is vital in managing inflammatory bowel disease, and we are pleased to have introduced this additional treatment option safely and smoothly. Biosimilars offer the same clinical benefits as the originator drug, while helping us make best use of NHS resources.”

The changeover to the biosimilar was carefully planned, with the pharmacy team, IBD specialist nurses, and consultant team all integral to the process, and colleagues ensured there was careful communication with and support for affected patients. Those patients who had additional questions or concerns were offered appointments in ad-hoc clinics, where they could discuss the change directly with a consultant and specialist pharmacist.

Introducing biosimilars has already delivered significant savings for the Trust. The move to Ustekinumab, along with previous biosimilar switches, has saved the Trust an estimated £4.9 million – funds which can be reinvested into patient care and service improvements.

Professor Andrew Brent, Chief Medical Officer at OUH, said: “This is an excellent example of how innovation, patient engagement, and clinical leadership come together to deliver high-quality, sustainable care. We are very proud of the work of our Gastroenterology and Pharmacy teams in making this transition a success.”